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Hepatocellular carcinomas (HCCs) arise from diverse etiological backgrounds and display 
remarkable biological and clinical heterogeneity. Unsupervised analyses of gene expression 
profiles variably subdivide HCCs into between two and six subclasses with distinct 
transcriptomic profiles and clinicopathologic features.(1-5) Nevertheless, HCC molecular 
subclassification has not been implemented in the clinic, hampered in part by a lack of 
consensus between the various classifications and their prognostic and, in particular, 
predictive implications. Sorafenib, the only approved systemic treatment, on average 
prolongs patient survival by 2.8 months.(6) However, robust predictive biomarkers for 
sorafenib response have not been defined. Indeed, prognostication and treatment decisions 
for HCC patients are currently made primarily based on the Barcelona Clinic Liver Cancer 
(BCLC) staging system.  
 
Nonetheless, several recurrent themes have emerged from the molecular analyses. HCCs 
can be broadly classified as proliferative and non-proliferative in roughly equal proportions. 
Compared to non-proliferative HCCs, proliferative HCCs are typically more aggressive and 
less differentiated,(3, 5) and are frequently associated with higher serum α-fetoprotein (AFP) 
levels, TP53 mutations and poor outcome.(1, 3, 4) Furthermore, proliferative HCCs may 
display TGF-β, MET, AKT, and/or IGF2 pathway activation(1-3) and/or the progenitor cell 
phenotype.(3) By contrast, the non-proliferative subgroup appears to be heterogeneous with 
less certain biological significance. While a subset (~30%) of the non-proliferative HCCs 
harbor mutations in β-catenin (encoded by CTNNB1) and show β-catenin pathway 
activation,(1-3, 5) there is no consensus on the distinguishing features of the remaining non-
proliferative HCCs. In the current issue of Hepatology, Désert et al.(7) further our 
understanding of non-proliferative HCCs through the lens of the metabolic zonation program 
of the liver. 
 
Liver parenchymal cells display a gradient of metabolic processes along the porto-central 
axis relative to the vascular structure of the liver (Figure 1). For instance, gluconeogenesis 
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and urea synthesis are primarily performed by hepatocytes near the portal vein (“periportal”) 
whereas lipogenesis and glycolysis are increased on the central end (“perivenous” or 
“pericentral”). β-catenin-mediated Wnt signaling and HNF4A-regulated gene networks play 
important roles in governing metabolic zonation,(8) where in the periportal hepatocytes, 
TCF4 induces the transcription of HNF4A-regulated genes in the absence of β-catenin and 
in the periportal hepatocytes, β-catenin allows TCF4 to bind to Wnt-response elements thus 
inducing the transcription of β-catenin-induced genes.(9) Through a meta-analysis of 1,113 
HCCs previously profiled using gene expression microarrays, Désert et al.(7) report that 
non-proliferative HCCs are divided into two distinct subclasses, each preserving the 
periportal or perivenous phenotypes of the metabolic zonation that is critical for normal liver 
functioning. 
 
To enable the prediction of CTNNB1 mutation status in the microarray metadata set, the 
investigators first defined a robust 5-gene signature using independent training and 
validation datasets with known CTNNB1 mutation status. The signature consists of three 
(GLUL, LRG5 and ODAM) and two (HAL and VNN1) genes whose expression positively and 
negatively, respectively, correlates with CTNNB1 mutation status. While GLUL and LRG5 
are well-known Wnt target genes, the remaining three constitute novel HCC biomarkers. 
Using HCC cell lines, the authors demonstrate that activating β-catenin signaling using 
GSK3β inhibitor 6-bromoindirubin-3′-oxime upregulates odontogenic ameloblast-associated 
protein (ODAM) and attenuates histidine ammonia lyase (HAL) and vanin 1 (VNN1) 
expression. Indeed, a network analysis of mouse liver periportal and perivenous signatures 
showed that, although ODAM, HAL and VNN1 were not present in the signatures, they were 
highly connected to the genes in the signatures. The 5-gene signature was found to have 
accuracies of 87% and 93% in the training and validation sets and was used to predict 
CTNNB1 mutations status for the meta-analysis. 
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The investigators report that hierarchical clustering of the 1,1113 HCCs revealed four 
subclasses with different prognoses. “ECM-type” (extracellular matrix) and “STEM-type” 
HCCs display signatures of high tumor cell proliferation and are associated with the S1/S2 
(Wnt/TGF-β, poor prognosis) subclasses.(3) Additionally, the “ECM-type” subclass is 
characterized by signatures of ECM modelling, integrin signaling, epithelial-to-mesenchymal 
transition, while the “STEM-type” subclass is enriched for cancer stem cell, metastasis, cell 
cycle progression and p53 mutation signatures. 
 
The remaining two subclasses display signatures of low proliferation and favorable 
prognosis and both show little intra-cluster variability. What is interesting, however, is that, 
gene set enrichment analyses revealed that these two classes reflect the tightly regulated 
metabolic zonation program of the liver (Figure 1). These two subclasses were named 
“perivenous-type” (PV) and “periportal-type” (PP) HCCs to reflect their resemblance to the 
phenotypes at the two ends of the metabolic zonation spectrum. The PV subclass is highly 
enriched for predicted CTNNB1 mutations and Wnt activation, the G6 subclass,(1) and 
perivenous hepatocyte gene signatures, including lipid and bile salt metabolism signatures. 
By contrast, the PP subclass is enriched for periportal hepatocyte gene signatures, such as 
those of gluconeogenesis and amino acid catabolism, and was enriched for the S3 
subclass.(3) Finally, given the role of HNF4A, the authors demonstrated that the expression 
profiles of PP-type HCCs show a strong enrichment of HNF4A-regulated genes. Clinically, 
PP, PV, ECM and STEM types form a continuum of increasingly aggressive clinical behavior 
in terms of tumor aggressiveness, TNM staging, BCLC stages, vascular invasion, serum 
AFP concentrations, overall survival and disease-free survival. 
 
The current study by Désert et al.(7) highlights the importance of interpreting HCC molecular 
classification in the context of basic liver biology and anatomy. Previous studies invariably 
identified a transcriptomically heterogeneous subset of well differentiated HCCs that display 
features consistent with or suggestive of hepatocytes. While some of these non-proliferative 
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HCCs harbor CTNNB1 mutations and show β-catenin pathway activation,(1-3, 5) there is no 
agreement on the biological significance of the CTNNB1-wild-type subset. When viewed 
from the perspective of metabolic zonation, Désert et al.(7) demonstrate that non-
proliferative HCCs recapitulate the phenotypes at the two distinct ends of the zonation 
program. In this context, the less aggressive clinical behavior of non-proliferative HCCs can 
be interpreted as their higher degree of preservation of normal liver phenotype. In particular, 
the lack of β-catenin activation in the PP-type HCCs would also be consistent with their least 
aggressive clinical and biological behavior. Notably, on the periportal vs perivenous 
spectrum, the only subclass that leans towards a perivenous phenotype is the PV-like, 
underscoring its unique biology compared to the other subclasses. Finally, the current study 
also provides a plausible explanation for the lack of prognostic difference between patients 
with CTNNB1-mutant or -wild-type HCCs,(10) as PV-type HCCs driven by β-catenin 
activation sit between proliferative HCCs and PP-type HCCs in terms of prognosis and 
highlights the molecular heterogeneity within the CTNNB1-wild-type subset. A more 
speculative interpretation of the current results raises the intriguing question of the cell of 
origin of HCCs. It remains to be seen whether the metabolic signatures observed in the 
various HCC subclasses merely reflect the metabolic programming along the porto-central 
axis or are indicative of their spatial origin. 
 
A contextualized view of HCC molecular subclassifcation is crucial towards understanding 
HCC biology and identifying drug targets that consider the unique biology of liver cancer. 
The study by Désert et al.(7) represents a significant step towards a unifying molecular 
classification of HCCs. Going forward, it will be of interest to validate the results from the 
current study on biopsy and resected HCC samples, aiming not only to obtain prognostic 
indicators but also to discover predictive biomarkers.  
 
 
  
 6 
REFERENCES 
1. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, 
Herault A, et al. Transcriptome classification of HCC is related to gene alterations and to 
new therapeutic targets. Hepatology 2007;45:42-52. 
2. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, et 
al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer 
Res 2008;68:6779-6788. 
3. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, 
et al. Integrative transcriptome analysis reveals common molecular subclasses of human 
hepatocellular carcinoma. Cancer Res 2009;69:7385-7392. 
4. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, et al. Classification 
and prediction of survival in hepatocellular carcinoma by gene expression profiling. 
Hepatology 2004;40:667-676. 
5. Makowska Z, Boldanova T, Adametz D, Quagliata L, Vogt JE, Dill MT, Matter MS, et 
al. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-
based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res 2016;2:80-92. 
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. 
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. 
7. Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, et al. Human 
Hepatocellular Carcinomas with a Periportal Phenotype Have the Lowest Potential for Early 
Recurrence after Curative Resection. Hepatology 2017. 
8. Gougelet A, Torre C, Veber P, Sartor C, Bachelot L, Denechaud PD, Godard C, et al. 
T-cell factor 4 and beta-catenin chromatin occupancies pattern zonal liver metabolism in 
mice. Hepatology 2014;59:2344-2357. 
9. Berasain C, Avila MA. Deciphering liver zonation: new insights into the beta-catenin, 
Tcf4, and HNF4alpha triad. Hepatology 2014;59:2080-2082. 

 7 
10. Rebouissou S, Franconi A, Calderaro J, Letouze E, Imbeaud S, Pilati C, Nault JC, et 
al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin 
activity associated with liver tumor progression. Hepatology 2016;64:2047-2061. 
 
FIGURE LEGEND 
Figure 1: Non-proliferative HCCs recapitulate metabolic zonation. The metabolic 
zonation program of the liver stipulates that the metabolic functions of hepatocytes form a 
spatial gradient in relation to their proximity to either the portal vein (“periportal”) or the 
central vein (“perivenous”). Periportal hepatocytes are involved in functions such as 
gluconeogenesis and amino acid catabolism, whereas perivenous hepatocytes perform 
functions such as glycolysis and lipogenesis. Non-proliferative hepatocellular carcinomas 
(HCCs) exhibit molecular features that are reminiscent of either the periportal (“periportal-
type HCC”) or the perivenous (“perivenous-type HCC”) hepatocytes. Periportal-type HCCs 
are associated with favorable outcome, well differentiated HCC and HNF4A-associated gene 
networks. Perivenous-type HCCs are associated with less favorable outcome, increased 
frequency of CTNNB1 mutations and β-catenin activation, and increased expression of 
metastasis gene signature. 
 
